Arcturus Therapeutics Holdings Inc. (ARCT) News

Arcturus Therapeutics Holdings Inc. (ARCT): $31.14

-0.08 (-0.26%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter ARCT News Items

ARCT News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

ARCT News Highlights

  • 500 - Internal server error
  • Over the past 18 days, the trend for ARCT's stories per day has been choppy and unclear. It has oscillated between 1 and 1.

Latest ARCT News From Around the Web

Below are the latest news stories about Arcturus Therapeutics Holdings Inc that investors may wish to consider to help them evaluate ARCT as an investment opportunity.

Global Familial Amyloid Polyneuropathy Market 2021 Future Set to Massive Growth with High CAGR value | Market Players: Pfizer, GSK, Ionis, Alnylam, Corino Therapeutics, Proclara Bioscience, Arcturus Therapeutics

The report on Global Familial Amyloid Polyneuropathy Market has been provided by researchers for a detailed understanding of market performance over an estimated period of time set from 2021 to 2026. However, this report has introduced a brief overview to provide the reader with better information on this report. This brief description contains a basic []

Jumbo News | July 23, 2021

Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences

SAN DIEGO, Calif., July 06, 2021--Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences

Yahoo | July 6, 2021

If You Had Bought Arcturus Therapeutics Holdings (NASDAQ:ARCT) Stock Three Years Ago, You Could Pocket A 285% Gain Today

It hasn't been the best quarter for Arcturus Therapeutics Holdings Inc. ( NASDAQ:ARCT ) shareholders, since the share...

Yahoo | July 5, 2021

Return On Capital Employed Overview: Arcturus Therapeutics

During Q1, Arcturus Therapeutics ''s (NASDAQ: ARCT ) reported sales totaled $2.13 million. Despite a 85.53% in earnings, the company posted a loss of $57.67 million. In Q4, Arcturus Therapeutics brought in $2.24 million in sales but lost $31.08 million in earnings. What Is Return On Capital Employed? Changes in earnings and sales indicate shifts in Arcturus Therapeutics''s Return on Capital Employed, a measure of yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company and Full story available on Benzinga.com

Benzinga | June 24, 2021

Looking Into Arcturus Therapeutics''s Return On Capital Employed

In Q1, Arcturus Therapeutics (NASDAQ: ARCT ) posted sales of $2.13 million. Earnings were up 85.53%, but Arcturus Therapeutics still reported an overall loss of $57.67 million. Arcturus Therapeutics collected $2.24 million in revenue during Q4, but reported earnings showed a $31.08 million loss. What Is Return On Capital Employed? Changes in earnings and sales indicate shifts in Arcturus Therapeutics''s Return on Capital Employed, a measure of yearly pre-tax profit relative to capital employed by a business. Generally, a Full story available on Benzinga.com

Benzinga | June 8, 2021

7 Best Vaccine Stocks for Their Pipeline Potential

These Covid-19 vaccine stocks may be late in the race, but they certainly have growth potential as we head into the summer.

Faisal Humayun on InvestorPlace | June 3, 2021

Primordial Genetics Grants Arcturus Therapeutics Exclusive License of an RNA Polymerase for Human and Animal Therapeutics

Primordial Genetics ("Primordial"), a synthetic biology company developing enzymatic production systems for nucleic acids, today announced granting Arcturus Therapeutics Holdings Inc. ("Arcturus", Nasdaq: ARCT), a clinical-stage messenger RNA (mRNA) medicines company, an exclusive license of an enzyme for an RNA polymerase (RNApol)

BioSpace | June 1, 2021

What Is The Ownership Structure Like For Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)?

The big shareholder groups in Arcturus Therapeutics Holdings Inc. ( NASDAQ:ARCT ) have power over the company...

Yahoo | May 21, 2021

Arcturus Therapeutics (NASDAQ:ARCT) Price Target Lowered to $33.00 at Barclays

Arcturus Therapeutics (NASDAQ:ARCT) had its price target lowered by Barclays from $46.00 to $33.00 in a research note published on Tuesday, The Fly reports. The brokerage currently has an equal weight rating on the biotechnology companys stock. A number of other equities analysts have also issued reports on ARCT. Zacks Investment Research upgraded Arcturus Therapeutics []

Dakota Financial News | May 12, 2021

Arcturus Therapeutics stock price target cut to $23 from $35 at B. Riley

This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news.

MarketWatch | May 12, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.594 seconds.